Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial

Timothy Craig, Markus Magerl, Donald S. Levy, Avner Reshef, William R. Lumry, Inmaculada Martinez‐Saguer, Joshua Jacobs, William H. Yang, Bruce Ritchie, Emel Aygören‐Pürsün, Paul K. Keith, Paula J. Busse, Henrike Feuersenger, Dipti Pawaskar, Iris Jacobs, Ingo Pragst, Mittie K. Doyle